These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31909698)

  • 1. Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas.
    Li X; Strasser B; Jafari-Khouzani K; Thapa B; Small J; Cahill DP; Dietrich J; Batchelor TT; Andronesi OC
    Radiology; 2020 Mar; 294(3):589-597. PubMed ID: 31909698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
    Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC
    Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
    Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
    Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
    Andronesi OC; Loebel F; Bogner W; Marjańska M; Vander Heiden MG; Iafrate AJ; Dietrich J; Batchelor TT; Gerstner ER; Kaelin WG; Chi AS; Rosen BR; Cahill DP
    Clin Cancer Res; 2016 Apr; 22(7):1632-41. PubMed ID: 26534967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma.
    Li X; Strasser B; Neuberger U; Vollmuth P; Bendszus M; Wick W; Dietrich J; Batchelor TT; Cahill DP; Andronesi OC
    Neurooncol Adv; 2022; 4(1):vdac071. PubMed ID: 35911635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.
    An Z; Tiwari V; Ganji SK; Baxter J; Levy M; Pinho MC; Pan E; Maher EA; Patel TR; Mickey BE; Choi C
    Magn Reson Med; 2018 Apr; 79(4):1851-1861. PubMed ID: 28833542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving D-2-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RF-receive/B
    Strasser B; Arango NS; Stockmann JP; Gagoski B; Thapa B; Li X; Bogner W; Moser P; Small J; Cahill DP; Batchelor TT; Dietrich J; van der Kouwe A; White J; Adalsteinsson E; Andronesi OC
    NMR Biomed; 2022 Jan; 35(1):e4621. PubMed ID: 34609036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
    J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D high-resolution imaging of 2-hydroxyglutarate in glioma patients using DRAG-EPSI at 3T in vivo.
    An Z; Tiwari V; Baxter J; Levy M; Hatanpaa KJ; Pan E; Maher EA; Patel TR; Mickey BE; Choi C
    Magn Reson Med; 2019 Feb; 81(2):795-802. PubMed ID: 30277274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
    Andronesi OC; Kim GS; Gerstner E; Batchelor T; Tzika AA; Fantin VR; Vander Heiden MG; Sorensen AG
    Sci Transl Med; 2012 Jan; 4(116):116ra4. PubMed ID: 22238332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.
    Elkhaled A; Jalbert LE; Phillips JJ; Yoshihara HAI; Parvataneni R; Srinivasan R; Bourne G; Berger MS; Chang SM; Cha S; Nelson SJ
    Sci Transl Med; 2012 Jan; 4(116):116ra5. PubMed ID: 22238333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
    Autry AW; Lafontaine M; Jalbert L; Phillips E; Phillips JJ; Villanueva-Meyer J; Berger MS; Chang SM; Li Y
    J Neurooncol; 2022 Aug; 159(1):43-52. PubMed ID: 35672531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.
    Choi C; Ganji SK; DeBerardinis RJ; Hatanpaa KJ; Rakheja D; Kovacs Z; Yang XL; Mashimo T; Raisanen JM; Marin-Valencia I; Pascual JM; Madden CJ; Mickey BE; Malloy CR; Bachoo RM; Maher EA
    Nat Med; 2012 Jan; 18(4):624-9. PubMed ID: 22281806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
    Kalinina J; Carroll A; Wang L; Yu Q; Mancheno DE; Wu S; Liu F; Ahn J; He M; Mao H; Van Meir EG
    J Mol Med (Berl); 2012 Oct; 90(10):1161-1171. PubMed ID: 22426639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
    Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
    J Neurosurg; 2020 Jan; 132(1):180-187. PubMed ID: 30611146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
    Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY
    Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute Metabolite Quantification in Individuals with Glioma and Healthy Individuals Using Whole-Brain Three-dimensional MR Spectroscopic and Echo-planar Time-resolved Imaging.
    Baboli M; Wang F; Dong Z; Dietrich J; Uhlmann EJ; Batchelor TT; Cahill DP; Andronesi OC
    Radiology; 2024 Sep; 312(3):e232401. PubMed ID: 39315894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis.
    Suh CH; Kim HS; Paik W; Choi C; Ryu KH; Kim D; Woo DC; Park JE; Jung SC; Choi CG; Kim SJ
    Radiology; 2019 Jun; 291(3):752-762. PubMed ID: 30990380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
    de la Fuente MI; Young RJ; Rubel J; Rosenblum M; Tisnado J; Briggs S; Arevalo-Perez J; Cross JR; Campos C; Straley K; Zhu D; Dong C; Thomas A; Omuro AA; Nolan CP; Pentsova E; Kaley TJ; Oh JH; Noeske R; Maher E; Choi C; Gutin PH; Holodny AI; Yen K; DeAngelis LM; Mellinghoff IK; Thakur SB
    Neuro Oncol; 2016 Feb; 18(2):283-90. PubMed ID: 26691210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.